Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koskinen, P.
Right arrow Articles by Frick, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koskinen, P.
Right arrow Articles by Frick, M. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 15, Issue 7 820-825, Copyright © 1992 by American Diabetes Association

ARTICLES

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

P Koskinen, M Manttari, V Manninen, JK Huttunen, OP Heinonen and MH Frick
First Department of Medicine, Helsinki University Central Hospital, Finland.

OBJECTIVE--To determine coronary heart disease (CHD) incidence among dyslipidemic subjects with non-insulin-dependent diabetes mellitus (NIDDM) and to assess the effect of lipid-modifying treatment on serum and lipoprotein lipids and the CHD incidence in these patients. RESEARCH DESIGN AND METHODS--Of the 4081 men participating in the Helsinki Heart Study, a coronary primary prevention trial with gemfibrozil in middle-aged men with high non-high-density lipoprotein (HDL) cholesterol (greater than 5.2 mM; 200 mg/dL), 135 had NIDDM at entry. The incidence of definite myocardial infarction and cardiac death and changes in serum and lipoprotein lipids were determined during the 5-yr trial in the NIDDM patients and compared with those observed in nondiabetic trial participants. RESULTS--Compared with nondiabetic subjects, NIDDM patients had lower HDL cholesterol (P less than 0.001), higher triglyceride concentration (P less than 0.0001), and greater body mass index (P less than 0.001), there were more hypertensive patients (P less than 0.001) among them. The incidence of myocardial infarction and cardiac death was significantly higher among diabetic than nondiabetic participants (7.4 vs. 3.3%, respectively, P less than 0.02). CHD incidence in the gemfibrozil-treated diabetic men (n = 59) was 3.4% compared with 10.5% in the placebo group (NS). In multivariate analysis, diabetes (P less than 0.05), age (P less than 0.0001), smoking (P less than 0.0001), low HDL cholesterol (P less than 0.05), and high low-density lipoprotein cholesterol (P less than 0.005) were independently related to CHD incidence. Gemfibrozil-induced serum and lipoprotein lipid changes in diabetic patients were similar to those observed in nondiabetic subjects. CONCLUSIONS--Compared with similarly dyslipidemic nondiabetic subjects, patients with NIDDM are at markedly increased risk of CHD. This elevated risk can be somewhat reduced by gemfibrozil.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 cfpHome page
B. Patasi and J. R. Conway
Enhancing diabetes care in family practice: A flow sheet
Can Fam Physician, September 1, 2008; 54(9): 1237 - 1238.
[Full Text] [PDF]

Home page
 JAMAHome page
B. V. Howard, M. J. Roman, R. B. Devereux, J. L. Fleg, J. M. Galloway, J. A. Henderson, Wm. J. Howard, E. T. Lee, M. Mete, B. Poolaw, et al.
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
JAMA, April 9, 2008; 299(14): 1678 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
M. J. Fowler
Microvascular and Macrovascular Complications of Diabetes
Clin. Diabetes, April 1, 2008; 26(2): 77 - 82.
[Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. Pedro-Botet
Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2008; 8(1): 22 - 27.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Avogaro, C. Giorda, M. Maggini, E. Mannucci, R. Raschetti, F. Lombardo, S. Spila-Alegiani, S. Turco, M. Velussi, E. Ferrannini, et al.
Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women: Impact of microvascular complications, treatment, and geographic location
Diabetes Care, May 1, 2007; 30(5): 1241 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Yang, N. Sambandam, X. Han, R. W. Gross, M. Courtois, A. Kovacs, M. Febbraio, B. N. Finck, and D. P. Kelly
CD36 Deficiency Rescues Lipotoxic Cardiomyopathy
Circ. Res., April 27, 2007; 100(8): 1208 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
N. R. Madamanchi and M. S. Runge
Mitochondrial Dysfunction in Atherosclerosis
Circ. Res., March 2, 2007; 100(4): 460 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Meyer, B. P. McGrath, and H. J. Teede
Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome
Diabetes Care, March 1, 2007; 30(3): 471 - 478.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. G. Duncan, J. L. Fong, D. M. Medeiros, B. N. Finck, and D. P. Kelly
Insulin-Resistant Heart Exhibits a Mitochondrial Biogenic Response Driven by the Peroxisome Proliferator-Activated Receptor-{alpha}/PGC-1{alpha} Gene Regulatory Pathway
Circulation, February 20, 2007; 115(7): 909 - 917.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. J. Abrahamson
A 74-Year-Old Woman With Diabetes
JAMA, January 10, 2007; 297(2): 196 - 204.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al.
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association
Circulation, January 2, 2007; 115(1): 114 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, et al.
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association
Diabetes Care, January 1, 2007; 30(1): 162 - 172.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. E. Molitch
Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. M. Grundy
Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds
J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Herrero, L. R. Peterson, J. B. McGill, S. Matthew, D. Lesniak, C. Dence, and R. J. Gropler
Increased Myocardial Fatty Acid Metabolism in Patients With Type 1 Diabetes Mellitus
J. Am. Coll. Cardiol., February 7, 2006; 47(3): 598 - 604.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. D Feher and R. S Elkeles
Fenofibrate in type 2 diabetes: The FIELD study: Fibrate Intervention and Event Lowering in Diabetes (FIELD)
The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 330 - 333.
[PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
L. F Van Gaal, F. Peiffer, and D. Ballaux
Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Meyer, B. P. McGrath, J. Cameron, D. Kotsopoulos, and H. J. Teede
Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4630 - 4635.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Staels and J.-C. Fruchart
Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Diabetes, August 1, 2005; 54(8): 2460 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
O. Jarvinen, J. Julkunen, T. Saarinen, J. Laurikka, and M. R. Tarkka
Effect of Diabetes on Outcome and Changes in Quality of Life After Coronary Artery Bypass Grafting
Ann. Thorac. Surg., March 1, 2005; 79(3): 819 - 824.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
D. S. Feig, V. A. Palda, L. Lipscombe, and with The Canadian Task Force on Preventive Health
Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Can. Med. Assoc. J., January 18, 2005; 172(2): 177 - 180.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Drexel, S. Aczel, T. Marte, W. Benzer, P. Langer, W. Moll, and C. H. Saely
Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?
Diabetes Care, January 1, 2005; 28(1): 101 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. K. Srinivasan, A. D. Grayson, and B. M. Fabri
On-Pump Versus Off-Pump Coronary Artery Bypass Grafting in Diabetic Patients: A Propensity Score Analysis
Ann. Thorac. Surg., November 1, 2004; 78(5): 1604 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. M. Huss and D. P. Kelly
Nuclear Receptor Signaling and Cardiac Energetics
Circ. Res., September 17, 2004; 95(6): 568 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Fam PractHome page
G. A Donker, D. M Fleming, F. G Schellevis, and P. Spreeuwenberg
Differences in treatment regimes, consultation frequency and referral patterns of diabetes mellitus in general practice in five European countries
Fam. Pract., August 1, 2004; 21(4): 364 - 369.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
V. Snow, M. D. Aronson, E. R. Hornbake, C. Mottur-Pilson, K. B. Weiss, and the Clinical Efficacy Assessment Subcommittee of t
Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, April 20, 2004; 140(8): 644 - 649.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. Vijan and R. A. Hayward
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Ann Intern Med, April 20, 2004; 140(8): 650 - 658.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. M. Prisant
Clinical Trials and Lipid Guidelines for Type II Diabetes
J. Clin. Pharmacol., April 1, 2004; 44(4): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Lawrence, J. Reid, G. J. Taylor, C. Stirling, and J. P.D. Reckless
Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. J. Stevens, R. L. Coleman, A. I. Adler, I. M. Stratton, D. R. Matthews, and R. R. Holman
Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66
Diabetes Care, January 1, 2004; 27(1): 201 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. Luciani, G. Nasso, M. Gaudino, A. Abbate, F. Glieca, F. Alessandrini, F. Girola, F. Santarelli, and G. Possati
Coronary artery bypass grafting in Type II diabetic patients: a comparison between insulin-dependent and non-insulin-dependent patients at short- and mid-term follow-up
Ann. Thorac. Surg., October 1, 2003; 76(4): 1149 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Wagner, O. Jorba, R. Bonet, J. Ordonez-Llanos, and A. Perez
Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3212 - 3217.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. Barter
Review: Reconsidering the value of fibrates: lessons from the trials
The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 162 - 167.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
G. Steiner
DAIS: how it relates to other lipid intervention studies in diabetes
The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 212 - 215.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
S. E. Inzucchi and J. M. Amatruda
Lipid Management in Patients With Diabetes: Translating guidelines into action
Diabetes Care, April 1, 2003; 26(4): 1309 - 1311.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Harris, K. Donahue, S. S. Rathore, P. Frame, S. H. Woolf, and K. N. Lohr
Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, February 4, 2003; 138(3): 215 - 229.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. L Williams, A. Vazir, and A. G Zaman
Review: The management of stable angina in diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 18 - 25.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. Ballinger
Do all diabetic patients need statins? A view from primary care
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 58 - 61.
[Abstract] [PDF]

Home page
 CirculationHome page
References
Circulation, December 17, 2002; 106(25): 3373 - 3421.
[Full Text]

Home page
 Arch Intern MedHome page
H. B. Rubins, S. J. Robins, D. Collins, D. B. Nelson, M. B. Elam, E. J. Schaefer, F. H. Faas, J. W. Anderson, and for the VA-HIT Study Group
Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Arch Intern Med, December 9, 2002; 162(22): 2597 - 2604.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Edelsberg, D. Weycker, and G. Oster
Response to Lamotte et al.
Diabetes Care, October 1, 2002; 25(10): 1899 - 1900.
[Full Text]

Home page
 J Am Coll CardiolHome page
T. Y. Goraya, C. L. Leibson, P. J. Palumbo, S. A. Weston, J. M. Killian, E. A. Pfeifer, S. J. Jacobsen, R. L. Frye, and V.e. L. Roger
Coronary atherosclerosis in diabetes mellitus: A population-based autopsy study
J. Am. Coll. Cardiol., September 4, 2002; 40(5): 946 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. M. Grundy, G. L. Vega, M. E. McGovern, B. R. Tulloch, D. M. Kendall, D. Fitz-Patrick, O. P. Ganda, R. S. Rosenson, J. B. Buse, D. D. Robertson, et al.
Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Arch Intern Med, July 22, 2002; 162(14): 1568 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. M. Haffner and R. B. Goldberg
New Strategies for the Treatment of Diabetic Dyslipidemia
Diabetes Care, July 1, 2002; 25(7): 1237 - 1239.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Lamotte, L. Annemans, A. Lefever, M. Nechelput, and J. Masure
A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients
Diabetes Care, February 1, 2002; 25(2): 303 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
A. D Timmis
Diabetes: Relationship to ischaemic heart disease
Br. Med. Bull., October 1, 2001; 59(1): 159 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. V. Selby, A. J. Karter, L. M. Ackerson, A. Ferrara, and J. Liu
Developing a Prediction Rule From Automated Clinical Databases to Identify High-Risk Patients in a Large Population With Diabetes
Diabetes Care, September 1, 2001; 24(9): 1547 - 1555.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. M. Renders, G. D. Valk, L. V. Franse, F. G. Schellevis, J. Th.M. van Eijk, and G. van der Wal
Long-Term Effectiveness of a Quality Improvement Program for Patients With Type 2 Diabetes in General Practice
Diabetes Care, August 1, 2001; 24(8): 1365 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
The American Diabetes Association's 48th Annual Advanced Postgraduate Course
Diabetes Care, August 1, 2001; 24(8): 1489 - 1495.
[Full Text] [PDF]

Home page
 Clin. DiabetesHome page
R. R. Henry
Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management
Clin. Diabetes, July 1, 2001; 19(3): 113 - 120.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
B. J. Ansell, A. Perez, A. M. Wagner, and G. Carreras
Appropriate First-Line Lipid-Lowering Therapy for Type 1 Diabetes Mellitus
Arch Intern Med, June 11, 2001; 161(11): 1461 - 1462.
[Full Text] [PDF]

Home page
 JRSMHome page
L. Foggensteiner, S. Mulroy, and J. Firth
Management of diabetic nephropathy
J R Soc Med, May 1, 2001; 94(5): 210 - 217.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. L. Sprecher and G. L. Pearce
How deadly is the "deadly quartet"?: A post-CABG evaluation
J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1159 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. F. Ammar Jr., D. D. Gutterman, L. A. Brooks, and K. C. Dellsperger
Impaired dilation of coronary arterioles during increases in myocardial O2 consumption with hyperglycemia
Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E868 - E874.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. B. Elam, D. B. Hunninghake, K. B. Davis, R. Garg, C. Johnson, D. Egan, J. B. Kostis, D. S. Sheps, E. A. Brinton, and for the ADMIT Investigators
Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial
JAMA, September 13, 2000; 284(10): 1263 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. A. Grover, L. Coupal, H. Zowall, and M. Dorais
Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?
Circulation, August 15, 2000; 102(7): 722 - 727.
[Abstract] [Full Text] [PDF]